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Simple Summary: The current paradigm concerning metastatic spread in uveal melanoma is that the
critical point for dissemination occurs prior to presentation and that treatment of the primary tumor
does not change outcome. However, we show that patients with small uveal melanomas with genetic
characteristics typical for high risk for metastatic disease have a lower mortality rate from metastatic
disease, if treated earlier. Our data demonstrate that such small melanomas are potentially lethal
(like larger tumors), but that there is a window of opportunity to prevent life-threatening metastatic
spread if actively treated, rather than being monitored, as is often done currently.
Abstract: Our aim was to determine whether size impacts on the difference in metastatic mortality of
genetically high-risk (monosomy 3) uveal melanomas (UM). We undertook a retrospective analysis
of data from a patient cohort with genetically characterized UM. All patients treated for UM in the
Liverpool Ocular Oncology Centre between 2007 and 2014, who had a prognostic genetic tumor
analysis. Patients were subdivided into those with small (≤2.5 mm thickness) and large (>2.5 mm
thickness) tumors. Survival analyses were performed using Gray rank statistics to calculate absolute
probabilities of dying as a result of metastatic UM. The 5-year absolute risk of metastatic mortality
of those with small monosomy 3 UM was significantly lower (23%) compared to the larger tumor
group (50%) (p = 0.003). Small disomy 3 UM also had a lower absolute risk of metastatic mortality
(0.8%) than large disomy 3 UM (6.4%) (p = 0.007). Hazard rates showed similar differences even with
lead time bias correction estimates. We therefore conclude that earlier treatment of all small UM,
particularly monosomy 3 UM, reduces the risk of metastatic disease and death. Our results would
support molecular studies of even small UM, rather than ‘watch-and-wait strategies’.
Keywords: uveal melanoma; monosomy 3; metastatic risk
1. Introduction
The success of local control of primary uveal melanoma (UM) with radiotherapy or
surgery is high (80–100%, depending on treatment modality) [1–6]. Recent advances in
treatment regimens and the advent of intraocular laser therapies and drugs have increased
the rates of eye- and vision retention [7–11]. Although certain treatments for metastatic
UM, such as monoclonal antibody infusions or hepatic resections of isolated lesions, have
shown some benefit [12–21], they are suitable for only select UM patients [22–25]. Clinical
trials are underway for other treatments for patients with metastatic disease [26]; however,
to date, the prognosis remains poor and the metastatic mortality rate associated with UM
remains at 40–45% [27–31].
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Prognostic parameters associated with an increased risk of developing metastatic UM are
related to primary tumor characteristics, such as larger size, ciliary body involvement, extra-
ocular extension and histologic features (e.g., epithelioid cell morphology, closed connective
tissue loops, high mitotic count) [32–34]. In addition, chromosomal alterations, particularly
loss of one copy of chromosome 3 (monosomy 3; M3) and gene mutations (e.g., in BAP1,
SF3B1 and EIF1AX) play a major role in determining metastatic risk in UM [33,35–41]. At
the Liverpool Ocular Oncology Centre (LOOC), metastatic risk is determined using the
Liverpool Uveal Melanoma Prognosticator Online (LUMPO) algorithm that incorporates
clinical, histological and genetic parameters, to provide an individualized approach to
patient management [33]. This prognostic algorithm has been validated externally in
multiple centers worldwide [42–44].
Many UM patients present with advanced ocular disease, with approximately 23%
reporting that their tumor was initially missed when they presented with symptoms [45,46].
Previously, it had been considered that systemic tumor cell dissemination occurs prior
to presentation, and hence that ocular treatment does not reduce the risk of metastatic
disease and mortality. However, there are indications that earlier detection and treatment
of smaller UM are not only associated with better local outcomes but may also be associated
with improved survival rates [47–53].
Herein, to address the question of whether earlier treatment of UM would result in a
reduction in mortality from metastatic melanoma, we present an analysis of the outcomes
of UM patients with high-risk monosomy 3 UM (M3-UM), comparing their absolute risks
of mortality according to tumor size. Our hypothesis is that earlier detection and treatment
of high-risk M3-UM may improve the patients’ chances of survival.
2. Results
During the 7-year study period, data were available for 940 patients whose UM
underwent genetic testing. Of these, 403 (43%) were classified as M3; 432 (46%) as D3; and
105 (11%) were unclassifiable. The median age at diagnosis was 61 years (mean 60; range
24–94 years) with a male: female ratio of 525:415 (1.26:1). The median tumor diameter
was 13.3mm (mean 14.3; range 1.8–26.0) and tumor thickness was 5.4mm (mean 6.5; range
0.7–18.3). Ciliary body involvement was present in 188 patients (Table 1).
Table 1. Baseline patient and tumor characteristics (median and range) and primary treatment of small and large tumor
categories.




Age at diagnosis (years) 59 (22–89) 62 (21–94)
Longitudinal base diameter (mm) 8.5 (1.8–19.8) 14.2 (2.3–26)
Tumor thickness (mm) 1.8 (0.7–2.5) 6.8 (2.6–18.3)
Ciliary body involvement 17 (8.7%) 169 (22.7%)
Primary treatment
Ruthenium-106 plaque brachytherapy 77 (39.2%) 145 (19.5%)
Proton beam radiotherapy 65 (33.2%) 132 (17.7%)
Trans scleral tumor resection 8 (4.1%) 60 (8.1%)
Endoresection 9 (4.6%) 33 (4.4%)
Primary enucleation 35 (17.9%) 372 (50.0%)
- PDT 1 (0.5%) 1 (0.1%)
Tumors were classified as ‘small’ (≤2.5 mm in thickness) (n = 196) and ‘large’ (>2.5 mm
in thickness) (n = 744). This size cut-off is based on the clinical risk factors previously
described for small melanocytic lesions [54] of 2 mm and the T1 staging of small melanomas
of 3 mm [55].
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As outlined in Table 1, primary treatment was enucleation in 407/940 (43%) patients;
proton beam radiotherapy in 197 (21%), ruthenium-106 plaque brachytherapy in 222 (24%);
photodynamic therapy in 2 (0.2%); trans-scleral local resection in 68 (7%); and transretinal
endoresection in 42 (4%) patients. One case in each group had incomplete data on primary
treatment. There were proportionally more cases treated with eye-conserving primary
radiotherapy (either ruthenium-106 plaque brachytherapy or proton beam radiotherapy)
in those with smaller tumors (72% vs. 37%, p < 0.00001), and higher rates of primary
enucleation in the larger UM group (50% vs. 18%, p < 0.00001).
Of the small category tumors, 122 UM were D3 (62%), 44 were M3 (22%), and 30 (15%)
were genetically unclassifiable. Of the large tumor group, 310 were D3-UM (42%), 359 were
M3 (48%) and 75 (10%) were genetically unclassifiable. Both the small UM D3 and M3
subgroups were compared to the larger UM D3 and M3 cohorts, in terms of absolute risk
of mortality due to metastasis (Figure 1). The Gray statistics showed significant evidence
of an absolute risk difference between small and large M3-UM (p = 0.003) and between
small and large D3-UM (p = 0.007). The small and large UM categories were also compared
in terms of absolute risk of mortality (Figure 2). The Gray statistics (stratified by genetic
class) also showed significant evidence of an absolute risk difference between small and
large UM (p < 0.001).
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In particular, the 5-year absolute risk of mortality of small M3-UM was 23% versus
larger M3-UM at 50% (small D3-UM 0.8%; large D3-UM 6.4%).
Log-rank analysis also demonstrated a significant difference in the hazard rates of
small M3 versus large M3 UM (p = 0.003), between small D3 and large D3 UM (p = 0.007)
and between each of the remaining subgroup comparisons (p < 0.001).
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The relative risk (RR) f eath over 5 years was 0.45 (95% CI 0.26–0.8) in the smaller
M3 U group compared to the larger M3 group, and the hazard ratio (HR) was 0.44
(95% CI 0.30–0.58). Assuming ‘sojourn time’ of 1 year for detectability to symptomatology
to correct for lead time bias as previously described [52], the modified RR of death was 0.69
(95% CI 0.45–1.05) and the modified HR was 0.67 (95% CI 0.53–0.81) (Table 2). The rates
did not change significantly after 5-year correction for length time bias at a range of time
courses (Appendix A).
Table 2. Risk ratio and hazard rates of death for small M3 tumors in comparison to larger M3 UM.
Lead time bias correction with an estimated sojourn time of 1 year still demonstrates a lower risk of
death due to metastatic disease.
Risk Ratio and Hazard Rates RR (95% CI) HR (95% CI)
Uncorrected 0.45 (0.26–0.80) 0.44 (0.30–0.58)
After lead time bias correction 0.69 (0.45–1.05) 0.67 (0.53–0.81)
After length time bias correction after 5 years 0.78 (0.69–1.01) 0.64 (0.5–1.03)
3. Discussion
Due to the peak of metastatic mortality occurring 2 years after enucleation for UM [56],
early hypotheses (Zimmerman–McLean–Foster) suggested that enucleation itself may
increase the risk of metastatic disease by systemic dissemination of tumor cells [57]. If this
study had been performed in the 1970s, proponents of the Zimmerman–McLean–Foster
hypothesis might have attributed the higher mortality in patients with larger tumors to
the treatment of such tumors by enucleation. This theory has been largely refuted by
the COMS study with similar mortality rates for those undergoing enucleation or plaque
brachytherapy [58,59]. It has therefore been assumed that hematogeneous dissemination of
UM cells occurs long before the primary tumor has been diagnosed [60]. Tumor doubling
time calculations support this hypothesis by suggesting that the metastatic dissemination
precedes the initial diagnosis and treatment [61,62]. Other studies suggest that most UM
patients have circulating tumor cells (CTC), whereby the genotypic and phenotypic profiles
of the CTCs match the primary tumor [62,63]. As such, there is a prevailing dogma that
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treatment of the primary UM is undertaken only to preserve vision (and, if possible, the
eye) but will not prevent metastatic disease. Alternate opinions propose, however, that
by “stemming the metastatic flow” of UM cells into the bloodstream, this could result in a
reduction in the subsequent CTC load, and consequently reduce metastatic risk [50,51,64].
That is, there may indeed be a window of opportunity for metastatic disease prevention by
treating UM earlier, and this would be particularly relevant in small lethal M3-UM [53].
It is well established in UM that various clinical risk factors, including tumor size, are
related to the risk of metastatic disease and subsequent mortality, with small incremental
increases in primary tumor size significantly affecting outcomes [47,65,66]. It has been
assumed that larger UM are innately more aggressive, as they have either high-risk genetic
factors from the outset or have accumulated these factors over time, termed ‘crescendo
malignancy’ [67]. On this basis, it is conventional practice in many ocular oncology centers
to monitor small, indeterminate uveal melanocytic tumors for months (or even years) until
growth is documented [68–72]. Weis et al. demonstrated that most of these indeterminate
lesions are low-risk D3-UM [73]. Our current study supports these findings, with 73%
of the small melanocytic tumors being D3; however, importantly, we demonstrate that
over one quarter (i.e., 27%) of these small lesions are M3-UM, and therefore have a high
metastatic risk. Furthermore, whilst most of these small UM are D3 at this stage, it is
unclear what proportion could subsequently transform into higher-risk M3-UM, if left
untreated. Certainly, there are reports of genetic heterogeneity within larger UM [67,74–77],
which suggests that there is an evolutionary process of uveal melanocytic lesions from low
to high genetic risk. In addition, we have previously demonstrated that asymptomatic
patients with UM identified via the annual UK national diabetic retinopathy screening
program have lower mortality than those detected via alternative routes [52]. Taking all
of these data into account, which suggest that early detection and treatment of UM may
enable the prolongation of life in patients, there could be justification for the consideration
of earlier treatment in small uveal melanocytic tumors. If these lesions are monitored,
adequate patient counselling and informed consent are vital. Afshar et al. described a
number of cases whereby patients were monitored for years by their optometrist or local
ophthalmologist without being informed that there was a possibility that their ‘suspicious
nevus’ was malignant; some of these patients were eventually found to have a lethal UM
when biopsy was ultimately performed [78]. On the other hand, it is also important to
emphasize here that we do not recommend treatment of all small, benign, melanocytic
lesions; it can indeed be difficult to differentiate benign nevi from small melanomas. These
are best assessed and treated by teams having the required expertise in ocular oncology
so as to avoid unnecessary visual loss whilst not delaying treatment of life-threatening
melanomas. For example, we were able to confirm malignancy in such small lesions by
performing biopsy using skills and techniques that are now widely available.
At present, unfortunately, it is not possible using the available clinical imaging technologies
to genetically subtype these small uveal melanocytic lesions. With the advent of artificial
intelligence and its application in ophthalmology, however, this may change [79]. Consequently,
at present, to determine the genetic status of the cells within an atypical uveal melanocytic
lesion, intraocular biopsies must be performed. Our previous experience indicates that this
procedure is safe in most patients and can be undertaken following radiotherapy [80,81].
In this analysis, we have attempted to control for lead time bias with previously
published methods [82] requiring an estimate of sojourn time, which is the unobserved
period of time during which the tumor is asymptomatic but detectable at screening, and
thus it artificially increases the follow-up time. Sojourn time estimation is a difficult problem
in general, particularly in UM, where often asymptomatic patients are detected at a routine
screening visit [45]. Therefore, we have created a range of estimates, as suggested for other
forms of cancer where sojourn time is undefined [82], in order to take this into account, as
previously described [52]. Although these calculations come with their limitations, these
corrected calculations have also supported a risk benefit of those small melanoma lesions
treated at an earlier stage.
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A weakness of our study is that only chromosome 3 aberrations were assessed. We
have demonstrated chromosome 3 status to be of the greatest predictive value in stratifying
metastatic risk [83]; as such, we have used this parameter in these small samples. Other
genetic alterations are well-known to contribute to an increased metastatic risk (e.g., gains
of chromosome 8q, class 2 gene expression profiles and BAP1 (BRCA associated protein 1)
mutations) [84–90]. We and others have developed bespoke next-generation sequencing
panels for UM requiring smaller DNA concentrations from small lesions, which can be
applied to a range of processed and size-varying samples [91,92]. The application of this
molecular panel in future UM cohorts may enable us to delve further into the genetic
interactions and intricacies of each patient subgroup with different sized tumors.
4. Methods
4.1. Study Design
We performed a retrospective case–control study of data from a cohort of UM patients
diagnosed at the LOOC over the period of 2007–2014, to enable a minimum of 5 years of
follow-up. All patients who had consented to genetic testing of their tumor were included.
The diagnosis of UM was established by the presence of clinical signs of malignancy (e.g.,
orange pigment, low ultrasound reflectivity, serous retinal detachment and/or documented
growth) and followed by treatment with local radiotherapy (with trans-scleral or trans-
retinal biopsy), tumor resection or enucleation. We analyzed data on all our cases with a
M3 or disomy 3 (D3) genetic result (see below). Tumors were classified as ‘small’ (≤2.5 mm
in thickness) and ‘large’ (>2.5 mm in thickness). This size cut-off is based on the clinical
risk factors previously described for small melanocytic lesions [54] of 2 mm and the T1
staging of small melanomas of 3 mm [55].
4.2. Clinical Methods
Date and certified cause of death were automatically provided by the National Health
Service (NHS) Cancer Registry, the patients having been flagged at the time of diagnosis.
International patients and those from Ireland were excluded from this study as their
outcomes were not recorded within this NHS database.
4.3. Tumor Sampling
Tumor sample collection included material obtained during enucleation, trans-scleral
tumor resection and primary tumor endoresection. Those undergoing radiotherapy as
primary treatment (either proton beam or ruthenium-106 plaque brachytherapy) were
biopsied by either the trans-scleral or trans-retinal route. Trans-retinal samples were
obtained with a 25-gauge vitreous cutter, as previously described [93,94]. Trans-scleral
biopsies were initially obtained with 25 g fine-needle aspiration (FNAB), then with Essen
forceps scleral flap technique.
4.4. Genetic Analysis
Tumor DNA extraction, DNA quality assessment and quantification were conducted,
as previously described [95,96]. Chromosome 3 aberrations were assessed by either mul-
tiplex ligation-dependent probe amplification (MLPA) (MRC-Holland, Amsterdam, The
Netherlands) or microsatellite analysis (MSA). MLPA and MSA methods have been previ-
ously described [95–99].
4.5. Statistical Analysis
Gray rank statistics [100] were utilized to assess the differences in absolute risks of
dying due to metastatic UM amongst the groups, enabling the consideration of competing
risks. Hazard rates were also compared with the standard log-rank test. Lead time and
length time biases were estimated according to the method described by Duffy et al. [82].
Cancers 2021, 13, 2267 7 of 12
5. Conclusions
Our study has shown that treatment of small M3-UM is potentially lifesaving in its
early stages. It is, therefore, necessary to identify and treat malignancy in these small,
potentially lethal lesions without delay, if necessary, after performing intraocular tumor
biopsies. There appears to be a survival benefit in treating all small UM to reduce the flow
of metastatic cells and, more controversially, perhaps also small D3 UM to prevent con-
version from low- to high-risk tumor characteristics, such as in those cases of developing
genetic heterogeneity. This challenges the prevailing paradigm that clinically significant
micrometastases occur prior to diagnosis of the ocular tumor, and suggests that a win-
dow of opportunity exists to reduce the flow of UM micrometastases and subsequent
incurable, lethal dissemination. This window may only be available in the early stages
of tumor development. Consequently, these small, lethal M3-UM may represent the only
melanocytic lesions for which ophthalmologists can indeed alter patient mortality outcome
with early treatment.
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0.5 0.5 0.1333 0.6707 0.7761 0.6617
0.6 0.5 0.1500 0.6363 0.7271 0.6141
0.7 0.5 0.1647 0.6035 0.6981 0.5913
0.4 0.5 0.1143 0.7061 0.8599 0.7631
0.3 0.5 0.0923 0.7416 1.0138 1.0298
0.5 0.6 0.1429 0.6294 0.7719 0.6701
0.6 0.6 0.1579 0.6064 0.7249 0.6210
0.7 0.6 0.1707 0.5831 0.6971 0.5962
0.4 0.6 0.1250 0.6513 0.8524 0.7689
0.3 0.6 0.1034 0.6708 1.0001 1.0001
0.5 0.7 0.1538 0.5941 0.7593 0.6652
0.6 0.7 0.1667 0.5798 0.7182 0.6211
0.7 0.7 0.1772 0.5644 0.6938 0.5980
0.4 0.7 0.1379 0.6064 0.8297 0.7502
0.3 0.7 0.1176 0.6152 0.9589 0.9334














0.5 0.4 0.1250 0.7193 0.7719 0.6377
0.6 0.4 0.1429 0.6702 0.7249 0.5996
0.7 0.4 0.1591 0.6258 0.6971 0.5830
0.4 0.4 0.1053 0.7735 0.8524 0.7252
0.3 0.4 0.0833 0.8328 1.0001 1.0002
0.5 0.3 0.1176 0.7769 0.7593 0.5941
0.6 0.3 0.1364 0.7087 0.7182 0.5767
0.7 0.3 0.1538 0.6502 0.6938 0.5711
0.4 0.3 0.0976 0.8573 0.8297 0.6382
0.3 0.3 0.0759 0.9529 0.9589 0.8022






No. of Cancers 332 44
Number with fup > 5 years 147 33
Number of deaths ≤ 5 years 165 10
5-year fatality rate 0.52 0.23
5-year survival 0.48 0.77 0.45 0.26–0.8 0.44 0.3–0.58
after Lead Time Bias correction
5-year fatality rate 0.52 0.35
5-year survival 0.48 0.65 0.69 0.45–1.05 0.67 0.53–0.81
after Length Time Bias correction
5-year fatality rate 0.52 0.40
5-year survival 0.48 0.60 0.78 0.69–1.01 0.64 0.57–1.03
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